Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cassia alata cream is a topical botanical drug candidate being developed by The University of The West Indies for the treatment of tinea versicolor, a common fungal skin infection caused by *Malassezia* yeast. Derived from the leaves of the *Cassia alata* plant (also known as *Senna alata*), the extract contains bioactive anthraquinones, most notably chrysophanic acid (chrysophanol), which possess significant antifungal activity. The mechanism of action involves the inhibition of fungal growth and the potential disruption of cell membrane integrity in dermatophytes and yeasts. This specific 20% cream formulation is currently undergoing clinical evaluation in a pilot study to establish its safety and therapeutic efficacy as a natural alternative to synthetic antifungal agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cassia alata cream.